1-5 of 5
Robert J. Glynn
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Health Care Utilization and Costs Associated With Empagliflozin in Older Adults With Type 2 Diabetes

Phyo Than Htoo, Mehdi NajafZadeh, Helen Tesfaye, Sebastian Schneeweiss, Deborah J. Wexler, Robert J. Glynn, Niklas Schmedt, Anouk Déruaz-Luyet, Lisette Koeneman, Julie M. Paik, Elisabetta Patorno
Journal: Diabetes Care
Diabetes Care 2024;47(11):1900–1907
https://doi.org/10.2337/dc24-0270
Published: 25 June 2024
View articletitled, Health Care Utilization and Costs Associated With Empagliflozin in Older Adults With Type 2 Diabetes
Open the PDF for Health Care Utilization and Costs Associated With Empagliflozin in Older Adults With Type 2 Diabetes in another window
Journal Articles

Comparative Cardiovascular Effectiveness and Safety of SGLT-2 Inhibitors, GLP-1 Receptor Agonists, and DPP-4 Inhibitors According to Frailty in Type 2 Diabetes

Alexander Kutz, Dae Hyun Kim, Deborah J. Wexler, Jun Liu, Sebastian Schneeweiss, Robert J. Glynn, Elisabetta Patorno
Journal: Diabetes Care
Diabetes Care 2023;46(11):2004–2014
https://doi.org/10.2337/dc23-0671
Published: 07 September 2023
View articletitled, Comparative Cardiovascular Effectiveness and Safety of SGLT-2 Inhibitors, GLP-1 Receptor Agonists, and DPP-4 Inhibitors According to Frailty in Type 2 Diabetes
Open the PDF for Comparative Cardiovascular Effectiveness and Safety of SGLT-2 Inhibitors, GLP-1 Receptor Agonists, and DPP-4 Inhibitors According to Frailty in Type 2 Diabetes in another window
Journal Articles

Trends in First-Line Glucose-Lowering Drug Use in Adults With Type 2 Diabetes in Light of Emerging Evidence for SGLT-2i and GLP-1RA

HoJin Shin, Sebastian Schneeweiss, Robert J. Glynn, Elisabetta Patorno
Journal: Diabetes Care
Diabetes Care 2021;44(8):1774–1782
https://doi.org/10.2337/dc20-2926
Published: 18 June 2021
View articletitled, Trends in First-Line Glucose-Lowering Drug Use in Adults With Type 2 Diabetes in Light of Emerging Evidence for SGLT-2i and GLP-1RA
Open the PDF for Trends in First-Line Glucose-Lowering Drug Use in Adults With Type 2 Diabetes in Light of Emerging Evidence for SGLT-2i and GLP-1RA in another window
Journal Articles

Comparative Effectiveness and Safety of Sodium–Glucose Cotransporter 2 Inhibitors Versus Glucagon-Like Peptide 1 Receptor Agonists in Older Adults

Elisabetta Patorno, Ajinkya Pawar, Lily G. Bessette, Dae H. Kim, Chintan Dave, Robert J. Glynn, Medha N. Munshi, Sebastian Schneeweiss, Deborah J. Wexler, Seoyoung C. Kim
Journal: Diabetes Care
Diabetes Care 2021;44(3):826–835
https://doi.org/10.2337/dc20-1464
Published: 11 February 2021
View articletitled, Comparative Effectiveness and Safety of Sodium–Glucose Cotransporter 2 Inhibitors Versus Glucagon-Like Peptide 1 Receptor Agonists in Older Adults
Open the PDF for Comparative Effectiveness and Safety of Sodium–Glucose Cotransporter 2 Inhibitors Versus Glucagon-Like Peptide 1 Receptor Agonists in Older Adults in another window
Journal Articles

Inflammation and Progressive Nephropathy in Type 1 Diabetes in the Diabetes Control and Complications Trial

Julie Lin, MD, MPH, Robert J. Glynn, PHD, Nader Rifai, PHD, JoAnn E. Manson, MD, DRPH, Paul M. Ridker, MD, MPH, David M. Nathan, MD, Debra A. Schaumberg, SCD, OD, MPH
Journal: Diabetes Care
Diabetes Care 2008;31(12):2338–2343
https://doi.org/10.2337/dc08-0277
Published: 01 December 2008
View articletitled, Inflammation and Progressive Nephropathy in Type 1 Diabetes in the Diabetes Control and Complications Trial
Open the PDF for Inflammation and Progressive Nephropathy in Type 1 Diabetes in the Diabetes Control and Complications Trial in another window
Includes: Supplementary data